Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: Isomorphic | Vintage Vibes

Demis Hassabis on his rush to ‘solve all disease’ and Isomorphic’s new $2.1 billion

Demis Hassabis talks to Fortune about how a $2.1 billion Series B will ‘turbocharge’ Isomorphic.

What drones and drug discovery have in common

What drones and drug discovery have in common

What do weapons and drug discovery have in common? Over the last 24 hours, billions of dollars and a lead investor.

DeepMind CEO Demis Hassabis’ Isomorphic Labs raises $2.1 billion led by Thrive Capital

DeepMind CEO Demis Hassabis’ Isomorphic Labs raises $2.1 billion led by Thrive Capital

AI-driven drug discovery firm Isomorphic Labs secured a massive $2.1 billion in Series B funding. This capital will fuel the expansion of their AI drug design engine and advance therapeutic candidates. The investment underscores strong confidence in their innovative approach to tackling diseases.

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Anthropic in talks to raise $30 billion at $900 billion valuation

AI firm Anthropic is in early talks to raise over thirty billion dollars. The company seeks a valuation exceeding nine hundred billion dollars. This funding aims to support its growing AI software demand. The deal could close by month-end. Anthropic is a leader in AI tools.

The Economic Times

Google’s Isomorphic Labs to raise over $2 billion in new funding

Alphabet's AI drug discovery firm, Isomorphic Labs, is reportedly close to securing over $2 billion in new funding, led by Thrive Capital. This significant investment aims to bolster its drug design engine and fuel global expansion, underscoring Alphabet's strategy of commercializing its advanced AI ventures.

The Economic Times

Inside Big Pharma and VC’s big bet on AI: You wouldn’t ‘want to fly an airplane designed by hand, but all of our drugs are designed like that’

Silicon Valley and Wall Street are pouring billions into AI drug discovery in a high-stakes bet to “solve” disease.

Five years after its debut, Google DeepMind's AlphaFold shows why science is AI's killer app

In five years since AlphaFold's debut, it has transformed basic biochemical research. But its long-term effect on drug discovery remains unclear.

inkl

Read news from The Economist, FT, and more,
with one subscription

Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: 'The Next Big Milestone Is…'

Alphabet Inc.'s (NASDAQ:GOOG) (NASDAQ:GOOGL) Isomorphic Labs says its first artificial-intelligence-designed medicines are nearly ready for human testing.

Isomorphic Labs has grand ambitions to 'solve all diseases' with AI. Now, it's gearing up for its first human trials

Isomorphic Labs has grand ambitions to 'solve all diseases' with AI. Now, it's gearing up for its first human trials

“One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to address that disease,” Colin Murdoch, Isomorphic Labs president and Google DeepMind's chief business officer said.

Demis Hassabis on Isomorphic’s $600 million raise, AI, and healthcare’s future

Demis Hassabis on Isomorphic’s $600 million raise, AI, and healthcare’s future

Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, talks to Fortune about his AI drug discovery startup, Isomorphic Labs.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Google DeepMind

Isomorphic Labs

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play